ETF Holdings Breakdown of APGE

News associated with APGE

Financial Review: Apogee Therapeutics (NASDAQ:APGE) vs. argenx (NASDAQ:ARGX)

argenx (NASDAQ:ARGX – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk. Profitability This table compares argenx and Apogee Therapeutics’ net […] - 2025-06-17 05:49:06

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of “Buy” from Brokerages

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is […] - 2025-06-16 07:11:05

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC raised its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 90.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,344 shares of the company’s stock after acquiring an additional 17,301 shares during the […] - 2025-05-30 08:34:59

Millennium Management LLC Has $5.90 Million Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Millennium Management LLC boosted its position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 44.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 130,171 shares of the company’s stock after purchasing an additional 40,162 shares during the period. Millennium Management LLC’s holdings in Apogee Therapeutics were […] - 2025-05-28 07:56:52

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $94.60 Consensus PT from Analysts

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in […] - 2025-05-27 08:56:59

ProShare Advisors LLC Increases Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

ProShare Advisors LLC grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 30.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,805 shares of the company’s stock after purchasing an additional 2,985 shares […] - 2025-05-26 08:18:49

Analyzing Apogee Therapeutics (NASDAQ:APGE) and Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Profitability This table compares Zura Bio and […] - 2025-05-06 05:30:46

Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the […] - 2025-04-21 05:14:46

KLP Kapitalforvaltning AS Acquires Shares of 5,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)

KLP Kapitalforvaltning AS bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,000 shares of the company’s stock, valued at approximately $226,000. Other large investors have also recently made changes to their […] - 2025-04-08 07:32:50

Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Reduced by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 1.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 110,827 shares of the company’s stock after selling 1,774 shares during the period. Bank of New York Mellon Corp’s holdings in Apogee Therapeutics were worth $5,020,000 […] - 2025-03-18 07:09:01

Apogee Therapeutics (NASDAQ:APGE) Now Covered by Citigroup

Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock. A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee […] - 2025-03-14 07:48:55

Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […] - 2025-03-12 06:56:50

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB trimmed its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 1,300 shares during the period. Handelsbanken Fonder AB’s holdings […] - 2025-03-04 08:46:55

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on […] - 2025-03-04 06:47:02

Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $89.71

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock […] - 2025-02-05 06:06:46

APGE institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	15,578	USD 682,472
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,530	USD 286,079
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	22,979	USD 1,006,710
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	22,979	USD 1,006,710
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	153	USD 6,703
Total =		68,219	USD 2,988,674

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer